Authors
Deepak L Bhatt, Keith A Fox, Werner Hacke, Peter B Berger, Henry R Black, William E Boden, Patrice Cacoub, Eric A Cohen, Mark A Creager, J Donald Easton, Marcus D Flather, Steven M Haffner, Christian W Hamm, Graeme J Hankey, S Claiborne Johnston, Koon-Hou Mak, Jean-Louis Mas, Gilles Montalescot, Thomas A Pearson, P Gabriel Steg, Steven R Steinhubl, Michael A Weber, Joan Booth, Eric J Topol, CHARISMA Investigators
Publication date
2005/9/1
Journal
American Heart Journal
Volume
150
Issue
3
Pages
401. e1-401. e7
Publisher
Mosby
Description
BACKGROUND
The manifestations of atherothrombosis such as myocardial infarction, ischemic stroke, limb ischemia, or cardiovascular death pose a global health care burden. Additional therapies to decrease ischemic events in patients with established vascular disease or at risk for developing vascular disease are necessary. We sought to characterize the risk factors and treatments of a diverse contemporary population of patients with atherothrombosis.
METHODS
The CHARISMA trial has enrolled 15603 patients from around the world. Patients with established coronary, cerebrovascular, or peripheral arterial disease, or those at high risk of developing atherothrombosis due to multiple risk factors, have been randomized to receive either the adenosine diphosphate receptor antagonist clopidogrel or placebo, in addition to background therapy with low- to moderate-dose aspirin.
RESULTS
A high percentage of …
Total citations
Scholar articles
DL Bhatt, KA Fox, W Hacke, PB Berger, HR Black… - American Heart Journal, 2005